Rimegepant Sulfate — Active Pharmaceutical Ingredient

Rimegepant Sulfate is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: TABLET, ORALLY DISINTEGRATING. Routes: ORAL.

This content is for informational purposes only. Always consult a healthcare professional.

Rimegepant Sulfate (1 brand name, 1 dosage form, 1 route)

Available dosage forms: TABLET, ORALLY DISINTEGRATING.

Routes of administration: ORAL.

Brand Names

  • NURTEC ODT

Contraindications

NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components. Reactions have included anaphylaxis and delayed serious hypersensitivity [see Warnings and Precautions (5.1) ].

Adverse Reactions

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: •Hypersensitivity Reactions [see Warnings and Precautions (5.1)] •Hypertension [see Warnings and Precautions (5.2)] •Raynaud’s Phenomenon [see Warnings and Precautions (5.3)]

Mechanism of Action

Rimegepant is a calcitonin gene-related peptide receptor antagonist.

Overdosage

There is limited clinical experience with NURTEC ODT overdosage. Treatment of an overdose of NURTEC ODT should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. No specific antidote for the treatment of rimegepant overdose is available. Rimegepant is unlikely to be significantly removed by dialysis because of high serum protein binding [see Clinical Pharmacology (12.3)].

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.